78 related articles for article (PubMed ID: 27012192)
21. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
22. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
23. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
[TBL] [Abstract][Full Text] [Related]
24. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro.
Ummanni R; Barreto F; Venz S; Scharf C; Barett C; Mannsperger HA; Brase JC; Kuner R; Schlomm T; Sauter G; Sültmann H; Korf U; Bokemeyer C; Walther R; Brümmendorf TH; Balabanov S
J Proteome Res; 2012 Apr; 11(4):2452-66. PubMed ID: 22424448
[TBL] [Abstract][Full Text] [Related]
25. Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer.
Steurer S; Hager B; Büscheck F; Höflmayer D; Tsourlakis MC; Minner S; Clauditz TS; Hube-Magg C; Luebke AM; Simon R; Izbicki JR; Burandt E; Sauter G; Fraune C; Weidemann S; Schlomm T; Heinzer H; Haese A; Graefen M; Huland H; Heumann A
Aging (Albany NY); 2019 Sep; 11(18):7859-7879. PubMed ID: 31557128
[TBL] [Abstract][Full Text] [Related]
26. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
Chakravarthi BVSK; Chandrashekar DS; Hodigere Balasubramanya SA; Robinson AD; Carskadon S; Rao U; Gordetsky J; Manne U; Netto GJ; Sudarshan S; Palanisamy N; Varambally S
Prostate; 2018 Dec; 78(16):1311-1320. PubMed ID: 30051493
[TBL] [Abstract][Full Text] [Related]
27. Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells.
Inokuchi J; Narula N; Yee DS; Skarecky DW; Lau A; Ornstein DK; Tyson DR
Int J Cancer; 2009 Jan; 124(1):68-74. PubMed ID: 18924133
[TBL] [Abstract][Full Text] [Related]
28. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
29. [Prostaglandin E2 promotes hepatocellular carcinoma cell proliferation through EP2 prostanoid receptor].
Guo D; Chen NN; Hou LB; Lei LS
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1564-7. PubMed ID: 21945767
[TBL] [Abstract][Full Text] [Related]
30. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.
Hobisch A; Rogatsch H; Hittmair A; Fuchs D; Bartsch G; Klocker H; Bartsch G; Culig Z
J Pathol; 2000 Jul; 191(3):239-44. PubMed ID: 10878544
[TBL] [Abstract][Full Text] [Related]
32. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.
Jiang J; Dingledine R
J Pharmacol Exp Ther; 2013 Feb; 344(2):360-7. PubMed ID: 23192657
[TBL] [Abstract][Full Text] [Related]
33. Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
Bergström SH; Järemo H; Nilsson M; Adamo HH; Bergh A
Prostate; 2018 Mar; 78(4):257-265. PubMed ID: 29250809
[TBL] [Abstract][Full Text] [Related]
34. ERG expression in multiple myeloma-A potential diagnostic pitfall.
Knief J; Reddemann K; Gliemroth J; Brede S; Bartscht T; Thorns C
Pathol Res Pract; 2017 Feb; 213(2):130-132. PubMed ID: 27913051
[TBL] [Abstract][Full Text] [Related]
35. Expression of ribosomal proteins in normal and cancerous human prostate tissue.
Arthurs C; Murtaza BN; Thomson C; Dickens K; Henrique R; Patel HRH; Beltran M; Millar M; Thrasivoulou C; Ahmed A
PLoS One; 2017; 12(10):e0186047. PubMed ID: 29016636
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.
Ganesh T
Expert Opin Ther Pat; 2015 Jul; 25(7):837-44. PubMed ID: 25772215
[TBL] [Abstract][Full Text] [Related]
37. Expression of interleukin 6 and its receptor in human gastric and colorectal cancers.
Matsuo K; Oka M; Murase K; Soda H; Isomoto H; Takeshima F; Mizuta Y; Murata I; Kohno S
J Int Med Res; 2003; 31(2):69-75. PubMed ID: 12760309
[TBL] [Abstract][Full Text] [Related]
38. Expression of prostaglandin E2 prostanoid receptor EP2 and interleukin-1β in laryngeal carcinoma - preliminary study.
Mochocki M; Morawski P; Kopta R; Brzezińska-Błaszczyk E; Stasikowska O; Lewy-Trenda I; ; Starska K
Contemp Oncol (Pozn); 2015; 19(2):113-9. PubMed ID: 26034388
[TBL] [Abstract][Full Text] [Related]
39. A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate Cancer.
Tessem MB; Bertilsson H; Angelsen A; Bathen TF; Drabløs F; Rye MB
PLoS One; 2016; 11(4):e0153727. PubMed ID: 27100877
[TBL] [Abstract][Full Text] [Related]
40. AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells.
Ikeuchi W; Wakita Y; Zhang G; Li C; Itakura K; Yamakawa T
Prostate; 2022 Jan; 82(1):97-106. PubMed ID: 34633095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
